TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00907374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benazepril
Description: benazepril 10 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benazepril
Description: 40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
Study: NCT04499586

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy Combined With Raltitrexed and Irinotecan
Description: Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) per week. Radiation: 45-55Gy/25-30Fx
Study: NCT00439556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study: NCT01125111

Intervention type: PROCEDURE
Intervention: surgery(robot versus laparoscopy)

Intervention type: PROCEDURE
Intervention: surgery(robot versus laparoscopy)
Study: NCT03507556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple paste and induced bleeding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
Description: triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
Study: NCT01944995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glasses broadband

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glasses broadband

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal CPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal CPAP
Study: NCT01642238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor + ASA + Bivalirudin
Description: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel + ASA + Bivalirudin
Description: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Study: NCT01725191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study: NCT04483024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate and chicken extract
Description: One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate and chicken extract
Description: One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen hydrolysate and chicken extract
Description: One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Collagen hydrolysate and chicken extract
Description: One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
Study: NCT01068938

Intervention type: DEVICE
Intervention: three different perimeters: HFA, Octopus, MATRIX
Description: visual fields
Study: NCT02736656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812
Study: NCT04360577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
Study: NCT03621878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization exercises -Tensioner technique
Description: Exercise aiming to lengthen the neural structure using more than one joint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization exercises -Slider technique
Description: Exercise aiming to slide/glide the neural structure using more than one joint.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Electrotherapy device aiming to decrease patient's symptoms.
Study: NCT02205593

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Regular follow-up and treatment WITHOUT behavioural intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Regular follow-up and treatment WITHOUT behavioural intervention
Study: NCT02139566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video consent (high-tech)
Description: Consent provided by an animated video with captions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video consent (low-tech)
Description: This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAQ format consent
Description: This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard consent
Description: The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDF informed consent document
Description: A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDF informed consent document
Description: A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDF informed consent document
Description: A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PDF informed consent document
Description: A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
Study: NCT04563845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin will be administered.
Study: NCT02358707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ibuprofen phonophoresis
Study: NCT01572129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in addition to the chronic daily dose of 75 mg
Study: NCT02053415

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil low dose
Description: 3 capsules krill oil per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil high dose
Description: 9 capsules krill oil per day
Study: NCT04582331

Intervention type: OTHER
Intervention: Smartphone-based voice and self-reported symptom collection
Description: Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study

Intervention type: OTHER
Intervention: Smartphone-based voice and self-reported symptom collection
Description: Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study

Intervention type: OTHER
Intervention: Smartphone-based voice and self-reported symptom collection
Description: Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
Study: NCT03648021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: \>50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~\>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
Study: NCT03290274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (fornix)
Description: Deep brain stimulation at fornix

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (Basal nucleus of Meynert)
Description: Deep brain stimulation AT Basal nucleus of Meynert
Study: NCT03754270

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advice in lifestyle
Description: Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive instructions and advice on lifestyle according to current clinical practice. Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical collar
Description: Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it. CC is marketed for indications of various diseases such as traumatic cervical injury, cervical disc herniation and other neck problems and allows adjustment of the elevation level to achieve sufficient effect, i.e., extending the neck.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
Study: NCT01693042

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary infusion of autologous bone marrow-derived cells
Description: Intracoronary infusion into open vessel / bypass supplying previous (\> 3 months) infarct area

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary infusion of autologous bone marrow-derived cells
Description: Intracoronary infusion into open vessel / bypass supplying previous (\> 3 months) infarct area
Study: NCT01743781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: view a 10-minute informational video about comprehensive eye examination
Study: NCT00148109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
Study: NCT03360695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Psychiatry Consultation (PPC)
Description: Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Psychiatry Consultation (PPC)
Description: Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
Study: NCT04159558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Experimental group will use a mobile application to help them in their self-care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Experimental group will use a mobile application to help them in their self-care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Experimental group will use a mobile application to help them in their self-care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Experimental group will use a mobile application to help them in their self-care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Experimental group will use a mobile application to help them in their self-care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Experimental group will use a mobile application to help them in their self-care
Study: NCT01600677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized medication delivery unit
Description: The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
Study: NCT04505891

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Kidney health education will be delivered prior to discharge by trained nurse educators.
Study: NCT02225626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other: standard breakfast
Description: tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
Study: NCT03975218

Intervention type: OTHER
Intervention: Patients With Stroke
Description: In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
Study: NCT00661310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug review 80+ -To reduce usage of hospital care
Description: drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
Study: NCT03306589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: 5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: 5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: 0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor
Description: 5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: 0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
Study: NCT04226053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenting, Child Development
Description: The treatment group will consist of mothers that were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby. The research-informed program model combines tailored, one-on-one sessions with an expert clinical social worker in-person every three months, provision of essential baby items including books, toys, clothing, and equipment (retail value of in-kind items over three years averages $10,000), and connections to vital community resources (e.g., housing, entitlements, child care, social services).
Study: NCT00965887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK0974 Ethanolate formulation
Description: Single dose MK0974 280 mg tablet in one of two treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: MK0974 Hydrate formulation
Description: Single dose MK0974 280 mg tablet in one of two treatment periods
Study: NCT03565380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated asymptomatic controls
Description: No intervention will be provided
Study: NCT03325374

Intervention type: OTHER
Intervention: Questionnaires and examination
Description: Patients with in the BLB patients study will have interview and questionnaire carried out.
Study: NCT02292563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopist only
Description: Only Colonosopist Observe during Colonoscopy (single observer)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopist only
Description: Only Colonosopist Observe during Colonoscopy (single observer)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experienced Endoscopy Nurse Participation
Description: Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experienced Endoscopy Nurse Participation
Description: Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
Study: NCT01913002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 800 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 2000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 2000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg
Study: NCT00920491

Intervention type: BIOLOGICAL
Intervention: biomarker-enhanced disposition decision with proADM
Description: To compare the outcome of standard of care with an approach combining the standardized course and biomarker levels (biomarker-enhanced disposition decision with proADM) for the disposition of patients with non-specific complaints presenting to the emergency department (ED), in order to evaluate safety.